A problem inherent to the use of cellular assays for drug discovery is their sensitivity to cytotoxic compounds, which can result in false hits from certain compound screens. To alleviate the need to follow-up hits from a reporter assay with a separate cytotoxicity assay, the authors have developed a multiplexed assay that combines the readout of a β-lactamase reporter with that of a homogeneous cytotoxicity indicator. Important aspects to the development of the multiplexed format are addressed, including results that demonstrate that the IC 50 values of 40 select compounds in a β-lactamase reporter assay for nuclear factor κ B and SIE pathway antagonists are not affected by the addition of the cytotoxicity indicator. To demonstrate the improvement in hit confirmation, the multiplexed assay was used to perform a small-library screen (7728 compounds) for serotonin 5HT1A receptor antagonists. Hits identified from analysis of the β-lactamase reporter data alone were compared to those hits determined when the reporter and cytotoxicity data generated from the multiplexed assay were combined. Confirmation rates were determined from compound follow-up using dose-response analysis of the potential antagonist hits identified by the initial screen. In this representative screen, the multiplexed assay approach yielded a 19% reduction in the number of compounds flagged for followup, with a 37% decrease in the number of false hits, demonstrating that multiplexing a β-lactamase reporter assay with a cytotoxicity readout is a highly effective strategy for reducing false hit rates in cell-based compound screening assays. (Journal of Biomolecular Screening 2007:635-644) commercially available analog of CCF2-AM, first described by Tsien and others. 7 Upon entering the cell, endogenous cytoplasmic esterases rapidly convert the CCF4-AM substrate to its negatively charged form, trapping it inside the cell. The charged form of the substrate fluoresces green upon excitation with 409 nm light due to FRET between coumarin and fluorescein moieties on the substrate. The β-lactamase catalyzes hydrolysis of the lactam ring, causing the substrate to undergo an elimination reaction, Hallis et al. 636 www.sbsonline.org Journal of Biomolecular Screening 12(5); 2007 FIG. 1. Mechanisms of CCF4-AM and the cytotoxicity indicator. Activation of transcription via a response element and the resulting expression of β-lactamase are monitored by a cell-permeable Förster resonance energy transfer (FRET)-based substrate (CCF4-AM), whereas cytotoxicity is evaluated by a cytotoxicity indicator. Upon entering the cell, endogenous cytoplasmic esterases rapidly convert the CCF4-AM and the cytotoxicity indicator to their negatively charged forms, trapping them inside the cell. The charged form of the CCF4-AM fluoresces green (A); upon β-lactamase hydrolysis of the lactam ring, the substrate undergoes an elimination reaction, resulting in the loss of FRET and a product that fluoresces blue (B). In the presence of live cells with intact membranes, the cytotoxicity indicator fluoresces red (C).
INTRODUCTION
C ELL-BASED REPORTER ASSAYS are rapidly gaining recognition for the value they bring to drug discovery. A significant advantage of cell-based assays is their potential to provide more biologically relevant information than biochemical assays. This is possible because cell-based assays allow a researcher to interrogate the molecular target in its cellular context including all components of the relevant physiological pathways, rather than in isolation as a single protein in solution. 1 Cellular assays are also inherently selective for compounds that are cell permeable and that are stable in a cellular environment. In addition, cell-based assays provide the option of being able to screen for agonists and antagonists, which is not always possible in simplified biochemical systems that often measure only the ability of a molecule to bind to a target protein. Cell culture automation and the ability to miniaturize cell-based assays have further contributed to their increased use in high-throughput screening for drug discovery. [2] [3] [4] Although powerful in their ability to represent relevant biology, cellular assays are subject to certain interferences that do not affect biochemical assays. One such interference is their sensitivity to cytotoxic compounds, which can result in false hits in certain compound screens. As such, it is common to follow up hit identification from cell-based assays with a separate secondary assay to detect cytotoxicity. 5, 6 Here, we discuss the development and examine the results of a multiplexed assay that combines a cell-based reporter assay with a cytotoxicity indicator.
The β-lactamase reporter assay uses the bacterial β-lactamase gene cloned downstream of a response element that is regulated in the pathway of interest. Stimulation of the pathway and activation of transcription leads to expression of β-lactamase, which is monitored using CCF4-AM, a cell-permeable Förster resonance energy transfer (FRET)-based substrate (Fig. 1) . 7 CCF4-AM is a resulting in the loss of FRET and a product that fluoresces blue. The combination of this FRET-based substrate with β-lactamase provides a very sensitive and robust cell-based assay that is easily miniaturizable for use in ultra-high-throughput screens. 8, 9 Advantages of this reporter system include the fact that there is no mammalian background, the enzymatic reaction provides amplification of the signal due to multiple substrate turnovers by β-lactamase, and the FRET substrate allows for a ratiometric readout that reduces noise in the assay. Also, the ability to read live cells allows for live cell sorting by flow cytometry and imaging by microscopy.
We have combined the β-lactamase reporter technology with a cytotoxicity indicator that reduces false hits by allowing detection of both the reporter gene expression and cytotoxicity from the same assay well without the need to perform separate cytotoxicity assays on putative hits. This multiplexed assay also enables the rapid identification of hits that are actually due to specific liquid-handling errors. Here, we discuss important aspects addressed during development of the multiplexed assay, including results that demonstrate that the IC 50 values from a screen of 40 select compounds in β-lactamase reporter assays using the SIE-bla ME-180 and the nuclear factor κ B (NF-κB)-bla ME-180 cell lines were not affected by the addition of the cytotoxicity indicator. A variety of different cell lines were used throughout the development to evaluate the versatility of the multiplexed assay. Once the assay had met the criteria necessary for screening, a 7728-compound screen for serotonin 5HT1A receptor antagonists was performed to demonstrate the improvement in hit confirmation. Results were analyzed 2 ways: first, using only the β-lactamase data to determine hits and then combining the β-lactamase and cytotoxicity data generated from the multiplexed assay. Confirmation rates were determined from compound follow-up using doseresponse analysis of the potential antagonist hits identified by the initial screen.
MATERIALS AND METHODS

Cell culture conditions
All cell culture reagents were from Invitrogen (Carlsbad, CA). Descriptions of the different cell lines mentioned throughout this article are summarized in Table 1 . The Jurkat parental cell line, obtained from ATCC (Manassas, VA), was maintained between 1 × 10 5 and 1.5 × 10 6 cells/mL in RPMI 1640 media supplemented with 10% dialyzed fetal bovine serum (FBS), 2 mM L-glutamine, 0.1 mM nonessential amino acids (NEAA), 1 mM sodium pyruvate, 25 mM HEPES (pH 7.3), 100 U/mL penicillin, and 100 µg/mL streptomycin. All other cell lines, with exceptions noted below, were maintained between 10% and 90% confluence in DMEM-based media supplemented with 10% dialyzed FBS, 0.1 mM NEAA, 1 mM sodium pyruvate, 25 mM HEPES (pH 7.3), 100 U/mL penicillin, and 100 µg/mL streptomycin. The media used to propagate the HRE-bla ME-180 and NF-κB-bla ME-180 cell lines (Invitrogen) were supplemented with 5 µg/mL of blasticidin. Media for 5HT1A-Gα15-NFAT-bla CHO-K1 cells (Invitrogen) included 50 µg/mL zeocin, 3 µg/mL blasticidin, and 600 µg/mL geneticin.
General assay method
The cytotoxicity indicator (proprietary, Invitrogen) and/or the CCF4-AM (LiveBLAzer™-FRET B/G substrate; Invitrogen) were dissolved separately in acetonitrile, mixed together in a proprietary ratio, and dried down under vacuum. The powder containing both the CCF4-AM and the cytotoxicity indicator was then dissolved in DMSO to a final concentration of 1 mM CCF4-AM (solution A + cytotoxicity indicator). Alternatively, CCF4-AM without the cytotoxicity indicator was dissolved in DMSO to a final concentration of 1 mM (solution A). Using the LiveBLAzer™-FRET B/G loading kit (Invitrogen), 6× substrate-loading solutions were prepared Antagonist assays were carried out in black-walled, clearbottom, 384-well assay plates (Corning, Acton, MA). Although the actual volumes and concentrations of reagents varied, final assay conditions were 0.1% or 0.5% DMSO in ∼40 µL. After incubating the cells in a 37 °C/5% CO 2 incubator with compounds for an optimized amount of time depending on the cell line (usually between 5 h and overnight), a 6× loading solution was added to a final 1 × concentration. The loading time was optimized for each assay and varied from 1 to 2 h at room temperature. Assay plates were read using a Tecan Safire 2 ™ fluorescent plate reader (Zurich, Switzerland) in bottom-read mode. Emission data from the β-lactamase substrate were collected at 460 nm (12-nm bandwidth) and 530 nm (12-nm bandwidth) using an excitation wavelength of 409 nm (12-nm bandwidth). Emission data from the toxicity indicator were obtained at 650 nm (12-nm bandwidth) using an excitation wavelength of 600 nm (20-nm bandwidth). IC 50 values were determined using nonlinear regression with an equation for sigmoidal dose response (variable slope) in XLFit4 (IDBS, Guildford, UK).
Effect of serum on the cytotoxicity signal
The signal to background of the cytotoxicity readout for wild-type Jurkat cells and HRE-bla ME-180 cells was analyzed at 3 different cell densities in the presence of 0.5%, 2.5%, or 10% dialyzed FBS in OptiMem ® -based media. Wild-type Jurkat suspension cells were plated at 30,000, 15,000, and 7500 cells/well in a 40-µL volume. Loading solution containing the cytotoxicity indicator (8 µL) was added to each well. The adherent HRE-bla ME-180 cells were plated at 20,000, 10,000, and 5000 cells/well in a 40-µL volume and incubated overnight at 37 °C/5% CO 2 before adding 8 µL of 6× loading solution containing the cytotoxicity indicator. No DMSO or compounds were added for this experiment.
Comparison of IC 50 values determined with CCF4-AM alone or with cytotoxicity indicator
NF-κB-bla ME-180 cells plated at 12,000 cells/well and SIE-bla ME-180 cells plated at 20,000 cells/well were serum starved for 16 to 20 h in a 32-µL volume of assay media (Opti-MEM ® media supplemented with 0.5% dialyzed FBS, 0.1 mM NEAA, 1 mM sodium pyruvate, 100 U/mL penicillin, and 100 ug/mL streptomycin). After serum starvation, cells were preincubated for approximately 30 min with a 10-point dilution series (10,000 nM to 0.3 nM) of 40 selected compounds (4 µL) prepared at 10 × in assay media prior to a 5-h stimulation with 4 µL of agonist prepared at 10 × the EC 80 in assay media. The EC 80 concentrations used were previously determined in an agonist dose-response curve and were as follows: 30 pM of interleukin (IL)-1β or 87 pM of tumor necrosis factor α (TNFα; both from Biosource, Camarillo, CA) for the NF-κB cell line and either 320 pM of IL-6 (R&D Systems, Minneapolis, MN) or 8.6 pM of interferon γ (IFNγ; Biosource) for the SIE cell line. The cells were then loaded with the 6× substrate-loading solution containing β-lactamase substrate alone or in combination with the cytotoxicity indicator.
Assessing the Z′ ′ factor of the cytotoxicity indicator
Similar volumes and assay conditions were used for the compound screen and for determining the Z′ factor to allow for data comparison. 5HT1A-Gα15-NFAT-bla CHO-K1 cells in DMEMbased assay media containing 2% FBS were plated at 12,500 cells/well in a 30-µL volume and incubated overnight at 37 °C/ 5% CO 2 . Cytotoxin (cetylpyridinium chloride; MicroSource Discovery Systems, Gaylordsville, CT; 4 µL) was added to 32 of the wells for a final concentration of 25 µM, whereas another 32 wells received only 4 µL of assay media containing 5% DMSO for a final concentration of 0.5% DMSO. All cells were stimulated with 5-carboxamidotryptamine (5 µL; Sigma, St. Louis, MO), at the EC 80 concentration of 150 nM. After a 4.5-h incubation, 10 µL of 4.9× substrate-loading solution containing the cytotoxicity indicator was added for a final volume of 49 µL, and the cells were loaded at room temperature for 2 h. The plate was read on a Tecan Safire using the same settings as described above, with the exception that a bandwidth of 12 nm was used for the excitation at 600 nm and the emission at 650 nm because a 20-nm bandwidth option was not available on this model. Assay quality was assessed by determining the Z′ factor according to Zhang and others. 10
Compound screen
5HT1A-Gα15-NFAT-bla CHO-K1 cells in DMEM-based assay media containing 2% FBS were plated at 12,500 cells/well in a 30-µL volume and incubated overnight at 37 °C/5% CO 2 . A subset of compounds (7728 compounds) from the Chembridge DIVERSet (Chembridge, San Diego, CA) were added to the cells (4 µL) for a final concentration of 5 µM (0.5% DMSO, n = 1). The nonspecific serotonin agonist, 5-carboxamidotryptamine, was then added to the cells (4 µL) at the EC 80 concentration of 150 nM, followed by a 5-h incubation. The following controls were included on each plate: unstimulated controls without 5-carboxamidotryptamine, no-cell controls, antagonist controls containing 5 µM of WAY-100635(N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate; Sigma), and cytotoxicity controls containing 25 µM cetylpyridinium chloride. The cells were loaded with 10 µL 4.8× substrate-loading solution containing cytotoxicity indicator for 2 h at room temperature for a final assay volume of 48 µL. Follow-up assays on compounds identified as antagonist hits in the initial screen were performed with serial dilutions of the compounds starting at 20 µM using the same volumes for cells and reagents as in the initial screen (0.5% DMSO, n = 3). All components for both the initial screen and the follow-up assays were added manually.
RESULTS AND DISCUSSION
Development of the multiplexed β β-lactamase reporter and cytotoxicity assay
Drug discovery programs are under constant pressure to reduce costs without jeopardizing their drug discovery pipeline. One approach is to reduce the cost of screening by lowering the number of false-positive results in a screen and avoiding unnecessary follow-up assays. Under some cell-based assay conditions, the presence of cytotoxic compounds can contribute to the number of false hits. To prevent testing on such compounds, researchers are increasingly performing cytotoxicity assays on their hits using a secondary, follow-up assay. As a way to facilitate the immediate identification of these false hits during the primary assay, we developed a multiplexed gene reporter assay that combines the β-lactamase reporter technology with a cytotoxicity indicator, eliminating the need to perform additional cytotoxicity assays.
The cytotoxicity indicator is a cell-permeable esterase substrate similar to those commonly used in cell viability studies. [11] [12] [13] Once inside the cell, the indicator is converted by nonspecific intracellular esterases into its red fluorescent product that is retained by cells with intact plasma membranes and is therefore concentrated in the cell (see Fig. 1 ). In contrast, the esterase activity in dead or damaged cells with compromised membranes is either absent or greatly reduced, resulting in very low red fluorescence. The degree of cytotoxicity is determined by the decrease in the red fluorescence from viable cells: The more cytotoxic the compound, the greater the number of dead cells and the lower the red fluorescence signal from the cytotoxicity indicator.
Before running the multiplexed assay in a screen, the assay was evaluated to ensure it possessed the characteristics necessary to meet the demands of high-throughput screening (HTS). Because screens are carried out over several days, with extended hours in a given day, it is highly desirable to use assays with stable, robust reagents to get consistent results from day to day. Therefore, we compared freshly prepared 6× substrate-loading solution containing both CCF4-AM and the cytotoxicity indicator to substrate-loading solution that had set at room temperature for various times, up to 24 h. The results showed negligible loss of signal even after 24 h, indicating that the substrateloading solution containing the cytotoxicity indicator need be prepared only once at the beginning of a full day of screening (data not shown).
During the development of the multiplexed assay, it was found that high concentrations of serum were causing a smaller cytotoxicity assay window. Endogenous esterases in serum can result in cleavage of the cytotoxicity indicator outside of the cell and thus increase the background in the cytotoxicity readout. To further investigate this effect, the signal-to-background ratio of the cytotoxicity signal was determined at 3 serum concentrations and at 3 different cell densities in an adherent (HRE-bla ME-180) and a suspension (wild-type Jurkat) cell line. Because only the signal from the cytotoxicity indicator was being analyzed, these cells were not treated with agonist or compounds. Instead, the highly red fluorescent signal from untreated, viable cells was compared to the weakly fluorescent no-cell control. As shown in Figure 2,  FIG. 2. Effect of serum on the cytotoxicity signal. The signal-tobackground ratio for the cytotoxicity indicator readout for HRE-bla ME-180 cells (A) and wild-type Jurkat cells (B) was analyzed at 3 different cell densities in the presence of 0.5%, 2.5%, or 10% dialyzed fetal bovine serum (FBS) in OptiMem ® -based media. Wild-type Jurkat suspension cells were plated at 30,000, 15,000, and 7500 cells/well and immediately loaded with 6× loading solution containing cytotoxicity indicator. The adherent HRE-bla ME-180 cells were plated at 20,000, 10,000, and 5000 cells/well and incubated overnight before the addition of a 6× loading solution containing the cytotoxicity indicator. No DMSO or compounds were added for this experiment.
both cell types show an increase in the signal-to-background ratio with increasing cell number and decreased serum concentration. Therefore, all future experiments were performed at 2% serum or lower for improved assay performance. From these data, it is apparent that the adherent cell line can achieve a larger assay window with a lower cell density than the suspension cell line, which is expected because adherent cells cover a larger surface area of the bottom of the assay plate than suspension cells. The graphs also indicate that the cytotoxicity signal correlates well to cell density.
To successfully provide both a gene reporter readout and a cytotoxicity readout in the multiplexed assay, it was critical that both readouts be independent of each other. The assay was designed to ensure that the excitation and emission wavelengths for the cytotoxicity indicator (600 and 650 nm, respectively) were removed from the blue and green emission signals of the CCF4-AM (460 and 530 nm). To confirm that the addition of the cytotoxicity indicator did not interfere with the β-lactamase readout, IC 50 values of 40 selected compounds were determined with the β-lactamase substrate alone or in combination with the cytotoxicity indicator in antagonist mode using SIE-bla ME-180 and NF-κB-bla ME-180 cell lines. The compound set was not pathway specific but included a variety of kinase inhibitors, cytotoxins, and structurally diverse compounds from the LOPAC library (Sigma). Figure 3 , which includes compounds with IC 50 values of ≤10,000 nM, shows very good correlation between the IC 50
FIG. 3.
Comparison of IC 50 values determined with CCF4-AM alone or with cytotoxicity indicator. SIE-bla ME-180 and nuclear factor κ B (NF-κB)-bla ME-180 cells were serum starved in 0.5% FBS for 16 to 20 h. After serum starvation, cells were preincubated with a dilution series from 10,000 to 0.3 nM of 40 selected compounds prior to a 5-h stimulation with either 30 pM of interleukin (IL)-1β or 87 pM of tumor necrosis factor α (TNFα) for the NF-κB cell line and either 320 pM of IL-6 or 8.6 pM of interferon γ (IFNγ) for the SIE cell line, all of which had previously been determined to be the EC 80 concentrations in an agonist dose-response curve. The cells were then loaded with either the 6× substrate-loading solution containing β-lactamase substrate alone or in combination with the cytotoxicity indicator. IC 50 values from both formats for those compounds that showed inhibition with IC 50 values of 10,000 nM or less are compared. BLA = β-lactamase; cyto ind = cytotoxicity indicator. values, with no trend of values being shifted higher or lower in either format. These results confirm that the cytotoxicity indicator does not affect IC 50 values and is therefore compatible with the β-lactamase reporter readout.
The most commonly used indicator of assay robustness in HTS is the Z′ factor. 10 Prior to running the representative compound screen for serotonin 5HT1A receptor antagonists described below, it was demonstrated that the cytotoxicity indicator can provide a robust readout in a 2-h read window. The Z′ factor from a 384-well plate of stimulated 5HT1A-Gα15-NFATbla CHO-K1 cells containing 2% serum was determined after half of the cells were treated with the cytotoxin cetylpyridinium chloride for 4.5 h (Fig. 4A) . Under these conditions, a signal-tobackground ratio of 3.5 and a Z′ value of 0.7 were calculated, indicating that even at a relatively low signal-to-background value, the assay is still robust, with a Z′ greater than 0.5.
Screening with the multiplexed β β-lactamase reporter and cytotoxicity assay
Once the multiplexed β-lactamase reporter/cytotoxicity assay had met the required performance criteria, it was used to perform a small compound single-point screen for serotonin 5HT1A receptor antagonists. A subset of compounds (7728 compounds) from the Chembridge DIVERSet library was chosen as a representative small library of diverse structures. Results from the screen were analyzed 2 ways: first, using only the β-lactamase blue/green data to determine hits and then combining the βlactamase and cytotoxicity data (red) generated with the multiplexed assay. For determining antagonist hits from the β-lactamase data, the cutoff threshold was set to achieve approximately a 0.5% hit rate, resulting in 37 potential antagonists (Fig. 5) . The cytotoxicity readout identified 14 compounds as potential cytotoxins using a threshold of 3 standard deviations from the average signal from all of the sample compounds. Seven of these 14 compounds were among the 37 antagonist hits ( Fig. 5) , indicating that 19% (7/37) of those hits were actually false.
To confirm that these were indeed false hits, all 37 compounds identified from the initial screen were evaluated in a follow-up dose-response analysis. The 7 hits identified as false by the cytotoxicity indicator showed no dose response in the follow-up βlactamase analysis as predicted, whereas 18 of the remaining 30 β-lactamase hits gave a clear dose response. A summary of the results in Figure 5 shows that using the combined information, the confirmed hit rate increased from 49% to 60%, with a 37% reduction in the number of false hits. Therefore, in this particular screen, the multiplexed assay reduced the number of compounds for follow-up by 19% (30 v. 37 hits) while maintaining the same 18 confirmed hits. Closer scrutiny of the data from the remaining compounds that did not give a dose response showed that 6 of the compounds were very close to the threshold for the initial screen, indicating they barely made the 0.5% hit rate cutoff to be counted as potential hits. In addition, 2 compounds had results that could not be fitted to the equation for a sigmoidal dose response with variable slope and were categorized as giving no dose response. The 14 compounds that were below the cytotoxicity threshold included a number of compounds that appeared to be neither antagonists nor cytotoxins in the follow-up dose-response experiments, suggesting that these original hits were due to other artifacts such as liquid-handling errors during the assay set up. As previously discussed, another advantage of the multiplexed approach is its ability to flag false hits due to specific pipetting errors that result in a very low fluorescence signal of the βlactamase substrate. Figure 6 (A and B) shows a representative set of data from the initial library screen. A histogram of the β-lactamase readout FIG. 4. Cytotoxicity and β-lactamase data from the Z′ factor determination for the cytotoxicity indicator. The cytotoxicity indicator red readout (A) and the β-lactamase blue/green readout (B) from the Z′ factor determination for the cytotoxicity indicator are plotted to illustrate the fluctuations in the β-lactamase readout for cells that are dead. The cytotoxin cetylpyridinium chloride was added to 32 wells of 5HT1A-Gα15-NFAT-bla CHO-K1 cells in DMEM-based assay media for a final concentration of 25 µM, whereas another 32 wells of cells received only assay media containing 5% DMSO for a final concentration of 0.5% DMSO. All cells were stimulated with 5-carboxamidotryptamine at the EC 80 concentration of 150 nM. After a 4.5-h incubation, substrate-loading solution containing the cytotoxicity indicator was added, and the cells were loaded at room temperature for 2 h.
indicates that the majority of compounds have a blue/green ratio of approximately 2.2. However, along with the unstimulated controls and cytotoxic controls, 2 additional compounds fell below the threshold for antagonist hits in plate 34, E22, and H23 (Fig. 6A) , and 1 compound (P15) fell well below the threshold in plate 27 (Fig. 6B) . The histograms of the cytotoxicity signal from the same plates show similar clustering for the library compounds except for compound E22 in plate 34 ( Fig.  6A) and compound P7 in plate 27 (Fig. 6B) , which, like the cytotoxicity controls, are below the cytotoxicity threshold, suggesting that they are cytotoxic. By combining the β-lactamase and cytotoxicity data from the multiplexed format, compound E22 would be flagged as a false antagonist hit, whereas H23 and P15 would be identified as true antagonist hits and would be selected for follow up.
An important consideration when confirming hits with follow-up dose-response analysis is the fact that cytotoxic compounds commonly display well-behaved IC 50 curves in the βlactamase readout (Fig. 6C) . Therefore, the additional cytotoxicity information provided with the multiplexed β-lactamase reporter/cytotoxicity assay is valuable, even in the dose-response follow-up. An example of 2 different hits from the 7728-compound screen is shown in Figure 6C . When only the β-lactamase doseresponse results are evaluated, both compounds appear to be true antagonists. However, when both the β-lactamase and cytotoxicity data are considered, the results clearly indicate that one compound (E22) is cytotoxic whereas the other (P15) is not.
Types of false positives that can be identified by the multiplexed assay
As cells begin to die, the signal intensity of a gene reporter assay may drop, depending on the stage and type of cell death. For those assays that are strictly based on signal intensity such as those that use luciferase, these types of results can falsely appear to be antagonists. The CCF4-AM substrate used with β-lactamase provides a ratiometric readout, using the blue and green signals of the cleaved and uncleaved substrate to determine β-lactamase expression. If the intensities of the blue and green signal decrease equally due to cell death, the blue/green ratio will not be affected. However, if the blue and green fluorescence do not drop evenly, the resultant ratio may indicate an agonist or an antagonist, depending on which signal drops more. One study has described an approach for scoring false hits due to cell toxicity in βlactamase assays through an analysis of raw blue or green fluorescence counts. 14 However, both the blue and green fluorescence are modulated by the level of FRET from the β-lactamase substrate and therefore must be interpreted with caution. The readout of the cytotoxicity indicator provides an independent signal that is not affected by the fluorescence from the β-lactamase substrate, therefore allowing separate determination of cell viability.
If a compound is so toxic that the cells are completely dead, the signal intensity of a gene reporter assay will likely drop to background. This result appears as a strong antagonist in most intensity-based gene reporter assays. In the case of β-lactamase reporter assays, the blue/green ratio may fluctuate, sometimes appearing as an agonist and sometimes as an antagonist. This is because the individual blue and/or green fluorescence intensities are actually in the background noise of the plate reader, causing arbitrary variations in the raw fluorescence units. This phenomenon is illustrated in Figure 4 , in which the cells that were lysed by treatment with a cytotoxin for the Z′ factor assessment of the cytotoxic indicator are graphed to show both the red cytotoxicity . The nonspecific serotonin agonist 5carboxamidotryptamine was then added to the cells at the EC 80 concentration of 150 nM, followed by a 5-h incubation. The cells were loaded with 6× loading solution containing cytotoxicity indicator. Results from the screen were analyzed 2 ways: first, using only the β-lactamase blue/green data to determine hits and then combining the β-lactamase and cytotoxicity data (red) generated with the multiplexed assay to eliminate false hits. For determining antagonist hits from the β-lactamase data, the cutoff threshold was set to achieve approximately a 0.5% hit rate, resulting in 37 potential antagonists. The cytotoxicity readout identified 14 compounds as potential cytotoxins using a threshold of 3 standard deviations from the average signal from all of the sample compounds, of 7 of these 14 compounds were among the 37 antagonist hits. Follow-up assays on compounds identified as antagonist hits in the initial screen were performed with serial dilutions of the compounds starting at 20 µM (0.5% DMSO, n = 3), with the same assay conditions as used for the initial screen. Those hits considered confirmed by dose response had results that could be fitted to the equation for a sigmoidal dose response with variable slope.
FIG. 6.
Representative data from the small-compound screen. Histograms of the β-lactamase blue/green readout and the cytotoxicity indicator red readout are shown for plate 34 (A) and plate 27 (B) of the 7728-compound screen. Compound E22 is flagged as both an antagonist and a cytotoxin in plate 34 (A), whereas compound P15 is identified as an antagonist and not cytotoxic in plate 27 (B). Th = threshold. Compounds E22 and P15 were followed up with a dose-response analysis using CCF4-AM containing the cytotoxicity indicator (C). When only the β-lactamase dose-response results are evaluated, both compounds appear to be true antagonists. However, when both the β-lactamase and cytotoxicity data are considered, it can be seen that compound E22 appears cytotoxic whereas compound P15 does not. data (Fig. 4A ) and the blue/green β-lactamase data (Fig. 4B) .
The results display widely fluctuating blue/green ratios that sometimes appear as agonists and sometimes as antagonists. Under these circumstances, the red cytotoxicity signal drops to background, allowing easy identification of such a highly toxic compound.
The signal intensity of a reporter assay can also drop significantly due to liquid-handling errors. Because the β-lactamase readout is ratiometric, it can accommodate significant variations in both cell number and substrate volume. However, if either the cell density or substrate concentration become so low that the blue or green fluorescent intensities are reduced to the background noise of the plate reader, the blue/green ratio can again fluctuate, potentially causing false hits. This scenario depicts another example of the types of artifacts that can be readily flagged by the cytotoxicity signal of the multiplexed assay.
CONCLUSION
We have developed ToxBLAzer™, a multiplexed assay that reduces false results in cellular reporter gene assays without additional liquid handling steps or extra assay set-up or incubation times. In this assay, analysis of cytotoxicity occurs at the same time, from the same assay well, and the same cells as the gene reporter assay. We have demonstrated that this multiplexed assay strategy improves hit-picking efficiency by eliminating false hits that may be due to either cytotoxic compounds or specific liquid-handling errors. Using the multiplexed assay in a representative screen of 7728 compounds, we were able to reduce the number of compounds for follow-up analysis by 19% (30 vs 37 hits) and increase the confirmed hit rate from 49% to 60%. In addition, the value of the cytotoxicity readout was illustrated for interpretation of follow-up dose-response curves in which cytotoxic compounds still appear as antagonists in the β-lactamase readout. The strategy reported here is a significant improvement compared to approaches requiring a separate follow-up cytotoxicity assay, in terms of ease of use, time, and associated assay costs.
